Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease
Open accessAbstract
IMPORTANCE: Cerebrospinal fluid (CSF) and positron emission tomographic (PET) amyloid biomarkers have been proposed for the detection of Alzheimer disease (AD) pathology in living patients and for the tracking of longitudinal changes, but the relation between biomarkers needs further study. OBJECTIVE: To determine the association between CSF and PET amyloid biomarkers (cross-sectional and longitudinal measures) and compare the cutoffs for these measures. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal clinical cohort study from 2005 to 2014 including 820 participants with at least 1 florbetapir F-18 (hereafter referred to as simply florbetapir)-PET scan and at least 1 CSF β-amyloid 1-42 (Aβ1-42) sample obtained within 30 days of each other (501 participants had a second PET scan after 2 years, including 150 participants with CSF Aβ1-42 measurements). Data were obtained from the Alzheimer's Disease Neuroimaging Initiative database. MAIN OUTCOMES AND MEASURES: Four different PET scans processing pipelines from 2 different laboratories were compared. The PET cutoff values were established using a mixture-modeling approach, and different mathematical models were applied to define the association between CSF and PET amyloid measures. RESULTS: The values of the CSF Aβ1-42 samples and florbetapir-PET scans showed a nonlinear association (R2 = 0.48-0.66), with the strongest association for values in the middle range. The presence of a larger dynamic range of florbetapir-PET scan values in the higher range compared with the CSF Aβ1-42 plateau explained the differences in correlation with cognition (R2 = 0.36 and R2 = 0.25, respectively). The APOE genotype significantly modified the association between both biomarkers. The PET cutoff values derived from an unsupervised classifier converged with previous PET cutoff values and the established CSF Aβ1-42 cutoff levels. There was no association between longitudinal Aβ1-42 levels and standardized uptake value ratios during follow-up. CONCLUSIONS AND RELEVANCE: The association between both biomarkers is limited to a middle range of values, is modified by the APOE genotype, and is absent for longitudinal changes; 4 different approaches in 2 different platforms converge on similar pathological Aβ cutoff levels; and different pipelines to process PET scans showed correlated but not identical results. Our findings suggest that both biomarkers measure different aspects of AD Aβ pathology.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mixture modeling provides an unbiased threshold for abnormality and is a well-established method for defining Aβ PET cut-offs.
“Mixture modeling statistics provide an unbiased threshold for abnormality (i.e., the diagnosis or status is not used in analysis) and it is a well-established method for defining Aβ PET cut-offs12, 17, 60, 61.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980 · see citing works
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · see citing works
Self-citationJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396 · see citing works
Self-citationPhases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · see citing works
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · see citing works
Self-citationMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,992 · cited 3× · see citing works
“There are several non– mutually exclusive explanations for this finding: (1) the changes are small and might not be detected owing to the inherent variability of the measurements, (2) a longer follow-up is needed to see larger changes, and (3) the different dynamic ranges of these 2 biomarkers could lead to different…”
Self-citationAlzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572 · see citing works
Self-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works
Self-citationAlzheimer’s Disease Neuroimaging Initiative
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W. J., Trojanowski, J. Q., Toga, A. W., & Beckett, L. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-72076-0_18 · Cited by 1,493 · see citing works
Self-citationThe Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348 · see citing works
Self-citationUse of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117 · see citing works
Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107 · see citing works
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Liu, E., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,011 · see citing works
Self-citationHoltzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · see citing works
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · see citing works
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · see citing works
The A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J. H., Donohue, M., Salmon, D. P., & Aisen, P. S. S. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 756 · see citing works
CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 604 · see citing works
Morris, J. C., & Price, J. L. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:101 · Cited by 513 · see citing works
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
De Meyer, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.179 · Cited by 462 · see citing works
Relationships between biomarkers in aging and dementia
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456 · see citing works
Self-citationLongitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434 · see citing works
Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid
Landau, S. M., Lu, M., Joshi, A. D., Pontecorvo, M., Mintun, M. A., Trojanowski, J. Q., Shaw, L. M., Jagust, W. J., & Initiative, F. T. A. D. N. (2013) · Annals of Neurology · doi:10.1002/ana.23908 · Cited by 401 · see citing works
Self-citationJoshi, A. D., Pontecorvo, M. J., Clark, C. M., Carpenter, A. P., Jennings, D. L., Sadowsky, C., Adler, L. P., Kovnat, K. D., Seibyl, J. P., Arora, A., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.090340 · Cited by 391 · see citing works
Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1358 · Cited by 368 · see citing works
Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353 · see citing works
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
Initiative, T. A. D. N., Shaw, L. M. J., Vanderstichele, H., Knapik-Czajka, M. E., Figurski, M., Coart, E., Blennow, K., Soares, H. D., Simon, A. J., Lewczuk, P., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0808-0 · Cited by 297 · see citing works
Self-citationGrimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278 · see citing works
Reducing between scanner differences in multi-center PET studies
Joshi, A., Koeppe, R. A., & Fessler, J. A. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.01.057 · Cited by 247 · see citing works
Cairns, N. J., Ikonomović, M. D., Benzinger, T. L. S., Storandt, M., Fagan, A. M., Shah, A. R., Taylor‐Reinwald, L., Carter, D. R., Felton, A., Holtzman, D. M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.279 · Cited by 203 · see citing works
Fagan, A. M., Shaw, L. M. J., Xiong, C., Vanderstichele, H., Mintun, M. A., Trojanowski, J. Q., Coart, E., Morris, J. C., & Holtzman, D. M. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.105 · Cited by 190 · see citing works
Self-citationCSF biomarkers cutoffs: The importance of coincident neuropathological diseases
Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M.-Y., Shaw, L. M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0983-7 · Cited by 182 · see citing works
Self-citationLongitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
Toledo, J. B., Xie, S. X., Trojanowski, J. Q., & Shaw, L. M. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1151-4 · Cited by 180 · see citing works
Self-citationFactors affecting Aβ plasma levels and their utility as biomarkers in ADNI
Toledo, J. B., Vanderstichele, H., Figurski, M., Aisen, P. S. S., Petersen, R. C., Weiner, M. W., Jack, C. R., Jagust, W., DeCarli, C. S., Toga, A. W., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0861-8 · Cited by 177 · see citing works
Self-citationRelationship of Cerebrospinal Fluid Markers to11C-PiB and18F-FDDNP Binding
Tolboom, N., van der Flier, W. M., Yaqub, M. M., Boellaard, R., Verwey, N. A., Blankenstein, M. A., Windhorst, A. D., Scheltens, P., Lammertsma, A. A., & van Berckel, B. N. M. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.064360 · Cited by 160 · see citing works
Wolk, D. A. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.153 · Cited by 156 · see citing works
Da, X., Toledo, J. B., Zee, J., Wolk, D. A., Xie, S. X., Ou, Y., Shacklett, A., Parmpi, P., Shaw, L. M. J., Trojanowski, J. Q., et al. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.11.010 · Cited by 135 · see citing works
Self-citationPlasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
Toledo, J. B., Shaw, L. M. J., & Trojanowski, J. Q. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt162 · Cited by 135 · see citing works
Self-citationThe neuropathological changes associated with normal brain aging.
Hof, P. R., Glannakopoulos, P., & Bouras, C. (1996) · PubMed · Cited by 106 · see citing works
Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
Mattsson, N., Insel, P. S., Landau, S. M., Jagust, W., Donohue, M., Shaw, L. M. J., Trojanowski, J. Q., Zetterberg, H., Blennow, K., Weiner, M. W., et al. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.81 · Cited by 106 · see citing works
Self-citationForsberg, A., Almkvist, O., Engler, H., Wall, A., Långström, B., & Nordberg, A. K. (2010) · Current Alzheimer Research · doi:10.2174/156720510790274446 · Cited by 104 · see citing works
Weigand, S. D., Vemuri, P., Wiste, H. J., Senjem, M. L., Pankratz, V. S., Aisen, P. S., Weiner, M. W., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.08.230 · Cited by 93 · see citing works
Self-citationIkonomovic, M., Abrahamson, E., Price, J., Hamilton, R., Mathis, C., Paljug, W. R., Debnath, M., Cohen, A., Mizukami, K., Dekosky, S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0943-2 · Cited by 90 · see citing works
Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
Toledo, J. B., Weiner, M. W., Wolk, D. A., Da, X., Chen, K., Arnold, S. E., Jagust, W., Jack, C., Reiman, E. M., Davatzikos, C., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-26 · Cited by 89 · see citing works
Self-citationRelationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI
Toledo, J. B., Da, X., Bhatt, P., Wolk, D. A., Arnold, S. E., Shaw, L. M. J., Trojanowski, J. Q., Davatzikos, C. A., & Initiative, A. D. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055531 · Cited by 47 · see citing works
Self-citationClark, V. H., Resnick, S. M., Doshi, J. J., Beason‐Held, L. L., Zhou, Y., Ferrucci, L., Wong, D. F., Kraut, M. A., & Davatzikos, C. A. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.01.010 · Cited by 38 · see citing works
Self-citationA comparison of Aβ amyloid pathology staging systems and correlation with clinical diagnosis
Boluda, S., Toledo, J. B., Irwin, D. J., Raible, K. M., Byrne, M., Lee, E. B., Lee, V. M. ‐., & Trojanowski, J. Q. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1308-9 · Cited by 30 · see citing works
Self-citationWorley, S. L. (2014) · PubMed · Cited by 5 · see citing works
Ikonomović, M. D., Price, J. C., Abrahamson, E. E., et al. (2012) · Neurology · doi:10.1212/wnl.78.1_meetingabstracts.s34.002 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952 · see citing works
Palmqvist, S., Schöll, M., Strandberg, O., Mattsson, N., Stomrud, E., Zetterberg, H., Blennow, K., Landau, S., Jagust, W., & Hansson, O. (2017) · Nature Communications · doi:10.1038/s41467-017-01150-x · Cited by 911 · see citing works
Self-citationHansson, O., Seibyl, J., Stomrud, E., Zetterberg, H., Trojanowski, J. Q., Bittner, T., Lifke, V., Corradini, V., Eichenlaub, U., Batrla, R., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.010 · Cited by 808 · see citing works
Self-citationImaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L., & Rowe, C. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.9 · Cited by 440 · see citing works
Palmqvist, S., Mattsson, N., Hansson, O., & Initiative, F. T. A. D. N. (2016) · Brain · doi:10.1093/brain/aww015 · Cited by 400 · see citing works
Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans
Saykin, A. J., Shen, L., Yao, X., Kim, S., Nho, K. T., Risacher, S. L., Ramanan, V. K., Foroud, T., Faber, K. M., Sarwar, N., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.009 · Cited by 301 · see citing works
Self-citationImpact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014
Weiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J. M., Donohue, M., Green, R. C., Harvey, D. J., Jack, C. R., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.04.005 · Cited by 240 · see citing works
Self-citationCentiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers
for the Alzheimer’s Disease Neuroimaging Initiative, F. T. A. S., Salvadó, G., Molinuevo, J. L., Brugulat-Serrat, A., Falcon, C., Grau-Rivera, O., Suárez-Calvet, M., Pavia, J., Niñerola-Baizán, A., Perissinotti, A., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0478-z · Cited by 195 · see citing works
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Alcolea, D., Pegueroles, J., Muñoz, L., Camacho, V., López‐Mora, D., Fernández‐León, A., Le Bastard, N., Huyck, E., Nadal, A., Olmedo, V., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50873 · Cited by 183 · see citing works
Morenas‐Rodríguez, E., Li, Y., Nuscher, B., Franzmeier, N., Xiong, C., Suárez‐Calvet, M., Fagan, A. M., Schultz, S., Gordon, B. A., Benzinger, T. L. S., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00027-8 · Cited by 177 · see citing works
Self-citationLa Joie, R., Bejanin, A., Fagan, A. M., Ayakta, N., Baker, S. L., Bourakova, V., Boxer, A. L., Cha, J., Karydas, A., Jerome, G., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000004860 · Cited by 141 · see citing works
Self-citationAlzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects
Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain · doi:10.1093/brain/awv199 · Cited by 136 · see citing works
Self-citationLeuzy, A., Chiotis, K., Hasselbalch, S. G., Rinne, J. O., de Mendonça, A., Otto, M., Lleó, A., Castelo-Branco, M. S., Santana, I. J., Johansson, J. J., et al. (2016) · Brain · doi:10.1093/brain/aww160 · Cited by 132 · see citing works
Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
Bjerke, M., & Engelborghs, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170680 · Cited by 132 · see citing works
Self-citationBlood-Based Proteomic Biomarkers of Alzheimer’s Disease Pathology
Baird, A. L., Westwood, S., & Lovestone, S. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00236 · Cited by 118 · see citing works
Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials
Sevigny, J., Suhy, J., Chiao, P., Chen, T., Klein, G., Purcell, D. D., Oh, J., Verma, A., Sampat, M. P., & Barakos, J. A. (2016) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000144 · Cited by 114 · see citing works
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110 · see citing works
Dementia with Lewy bodies: Impact of co‐pathologies and implications for clinical trial design
Toledo, J. B., Ruiz, C. A., Weil, R. S., Ferreira, D., Rodriguez‐Porcel, F. E., Pilotto, A., Wyman‐Chick, K. A., Grothe, M. J., Kane, J. P. M., Taylor, A., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12814 · Cited by 109 · see citing works
Self-citationThe Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans
Kang, J., Korecka, M., Figurski, M., Toledo, J. B., Blennow, K., Zetterberg, H., Waligórska, T., Brylska, M., Fields, L., Shah, N., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.003 · Cited by 98 · see citing works
Self-citationVos, S. J. B., Gordon, B. A., Su, Y., Visser, P. J., Holtzman, D. M., Morris, J. C., Fagan, A. M., & Benzinger, T. L. S. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.025 · Cited by 98 · see citing works
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 97 · see citing works
Self-citationDetecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults
Guo, T., Landau, S. M., Jagust, W. J., & Initiative, A. D. N. (2020) · Neurology · doi:10.1212/wnl.0000000000009216 · Cited by 92 · see citing works
Self-citationMyo-inositol changes precede amyloid pathology and relate toAPOEgenotype in Alzheimer disease
Voevodskaya, O., Sundgren, P. C., Strandberg, O. T., Zetterberg, H., Minthon, L., Blennow, K., Wahlund, L., Westman, E., Hansson, O., For the Swedish BioFINDER study group, et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002672 · Cited by 88 · see citing works
A Systematic Review of Longitudinal Studies Which Measure Alzheimer’s Disease Biomarkers
Lawrence, E., Vegvari, C., Ower, A. K., Hadjichrysanthou, C., de Wolf, F., & Anderson, R. M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170261 · Cited by 84 · see citing works
Iaccarino, L., Burnham, S. C., Dell’Agnello, G., Dowsett, S. A., & Epelbaum, S. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.43 · Cited by 81 · see citing works
Update on Biomarkers For Amyloid Pathology in Alzheimer’s Disease
Ashton, N. J., Schöll, M., Heurling, K., Gkanatsiou, E., Portelius, E., Höglund, K., Brinkmalm, G., Hye, A., Blennow, K., & Zetterberg, H. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0433 · Cited by 75 · see citing works
(ADNI), T. A. D. N. I., Bouallègue, F. B., Mariano‐Goulart, D., & Payoux, P. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0260-z · Cited by 71 · see citing works
Initiative, A. D. N., Roostaei, T., Nazeri, A., Felsky, D., Jager, P. L. D., Schneider, J. A., Pollock, B. G., Bennett, D. A., & Voineskos, A. N. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.35 · Cited by 70 · see citing works
Fantoni, E. R., Chalkidou, A., O’ Brien, J. T., Farrar, G., & Hammers, A. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171093 · Cited by 68 · see citing works
Palmqvist, S., Insel, P. S., Zetterberg, H., Blennow, K., Brix, B., Stomrud, E., Initiative, T. A. D. N., study, T. S. B., Mattsson, N., & Hansson, O. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.014 · Cited by 65 · see citing works
Guo, T., Korman, D., Joie, R. L., Shaw, L. M. J., Trojanowski, J. Q., Jagust, W. J., Landau, S. M., & Initiative, A. D. N. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00665-8 · Cited by 66 · see citing works
Self-citationTan, L., Wang, H.-F., Tan, M., Tan, C., Zhu, X., Miao, D., Yu, W.-J., Jiang, T., Tan, L., Yu, J., et al. (2016) · Scientific Reports · doi:10.1038/srep26027 · Cited by 63 · see citing works
Self-citationChallenges associated with biomarker‐based classification systems for Alzheimer's disease
Illán‐Gala, I., Pegueroles, J., Montal, V., Vilaplana, E., Carmona‐Iragui, M., Alcolea, D., Dickerson, B. C., Sánchez‐Valle, R., de Leon, M. J., Blesa, R., et al. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.03.004 · Cited by 62 · see citing works
Martínez, G., Vernooij, R. W. M., Padilla, P. F., Zamora, J., Bonfill, X., & Flicker, L. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012216.pub2 · Cited by 59 · see citing works
Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition
Tideman, P., Stomrud, E., Leuzy, A., Mattsson, N., Palmqvist, S., Hansson, O., & Initiative, A. D. N. (2022) · Neurology · doi:10.1212/wnl.0000000000013299 · Cited by 53 · see citing works
Imaging Alzheimer's disease pathophysiology with PET
Schilling, L. P., Zimmer, E. R., Shin, M., Leuzy, A., Pascoal, T. A., Benedet, A. L., Borelli, W. V., Palmini, A., Gauthier, S. G., & Rosa‐Neto, P. (2016) · Dementia & Neuropsychologia · doi:10.1590/s1980-5764-2016dn1002003 · Cited by 53 · see citing works
Rethinking on the concept of biomarkers in preclinical Alzheimer’s disease
Berti, V., Polito, C., Lombardi, G., Ferrari, C., Sorbi, S., & Pupi, A. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2477-1 · Cited by 51 · see citing works
Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults
Guo, T., Shaw, L. M. J., Trojanowski, J. Q., Jagust, W. J., Landau, S. M., & Initiative, A. D. N. (2020) · Neurology · doi:10.1212/wnl.0000000000010596 · Cited by 51 · see citing works
Self-citationBubu, O. M., Umasabor‐Bubu, O. Q., Turner, A. D., Parekh, A., Mullins, A. E., Kam, K., Birckbichler, M. K., Mukhtar, F., Mbah, A. K., Williams, N. J., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12184 · Cited by 54 · see citing works
Perez, S. E., Miguel, J. C., He, B., Malek‐Ahmadi, M. H., Abrahamson, E. E., Ikonomović, M. D., Lott, I. T., Doran, E. W., Alldred, M. J., Ginsberg, S. D., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01965-6 · Cited by 47 · see citing works
Neuroimaging biomarkers in Alzheimer’s disease and other dementias
Villemagne, V. L., & Chételat, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.004 · Cited by 48 · see citing works
Memory, executive, and multidomain subtle cognitive impairment
Toledo, J. B., Bjerke, M., Chen, K., Rozycki, M., Jack, C. R., Weiner, M. W., Arnold, S. E., Reiman, E. M., Davatzikos, C. A., Shaw, L. M. J., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001738 · Cited by 48 · see citing works
Self-citationRole of Neuroimaging as a Biomarker for Neurodegenerative Diseases
Shimizu, S., Hirose, D., Hatanaka, H., Takenoshita, N., Kaneko, Y., Ogawa, Y., Sakurai, H., & Hanyu, H. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00265 · Cited by 47 · see citing works
Müller, E. G., Edwin, T. H., Stokke, C., Navelsaker, S. S., Babovic, A., Bogdanović, N., Knapskog, A., & Revheim, M. E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221365 · Cited by 47 · see citing works
State of Play in Alzheimer’s Disease Genetics
Zhu, J.-B., Tan, C., Tan, L., & Yu, J. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170062 · Cited by 43 · see citing works
Timmers, M., Tesseur, I. C., Bogert, J., Zetterberg, H., Blennow, K., Börjesson‐Hanson, A., Baquero, M., Boada, M., RANDOLPH, C. C., Tritsmans, L., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.03.016 · Cited by 42 · see citing works
Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients
Bjorkli, C., Sandvig, A., & Sandvig, I. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00272 · Cited by 41 · see citing works
Sala, A., Nordberg, A. K., Rodriguez‐Vieitez, E., & Initiative, A. D. N. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00950-w · Cited by 43 · see citing works
Carandini, T., Arighi, A., Sacchi, L., Fumagalli, G. G., Pietroboni, A. M., Ghezzi, L., Colombi, A., Scarioni, M., Fenoglio, C., De Riz, M. A., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0543-7 · Cited by 36 · see citing works
Westwood, S., Baird, A. L., Hye, A., Ashton, N. J., Nevado‐Holgado, A. J., Anand, S. N., Liu, B., Newby, D., Bazenet, C. E., Kiddle, S. J., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00409 · Cited by 35 · see citing works
Amyloid beta in nasal secretions may be a potential biomarker of Alzheimer’s disease
Kim, Y. H., Lee, S.-M., Cho, S., Kang, J., Minn, Y., Park, H., & Choi, S. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-41429-1 · Cited by 37 · see citing works
APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points
Toledo, J. B., Habes, M., Sotiras, A., Bjerke, M., Yong Fan, A., Weiner, M. W., Shaw, L. M. J., Davatzikos, C. A., Trojanowski, J. Q., & Initiative, A. D. N. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181282 · Cited by 33 · see citing works
Self-citationPredicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
Wisch, J. K., Gordon, B. A., Boerwinkle, A. H., Luckett, P. H., Bollinger, J. G., Ovod, V., Li, Y., Henson, R. L., West, T., Meyer, M. R., et al. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12405 · Cited by 33 · see citing works
Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer’s Disease
Edmonds, E. C., Bangen, K. J., Delano‐Wood, L., Nation, D. A., Furst, A. J., Salmon, D. P., Bondi, M. W., & Initiative, A. D. N. (2016) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617716000928 · Cited by 27 · see citing works
Lin, S.-Y., Lin, K., Lin, P.-C., Huang, C.-C., Chang, C., Lee, Y., Hsiao, I., Yen, T., Huang, W.-S., Yang, B., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0566-0 · Cited by 26 · see citing works
Jung, N., Kim, E. S., Kim, H.-S., Jeon, S., Lee, M. J., Pak, K., Lee, J., Lee, Y. M., Lee, K., Shin, J., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191109 · Cited by 25 · see citing works
Kim, H. J., Lim, T. S., Lee, S. M., Kim, T.-S., Kim, Y., An, Y., Youn, Y. C., Park, S. A., Chang, J., & Moon, S. Y. (2019) · Journal of Clinical Neurology · doi:10.3988/jcn.2019.15.3.353 · Cited by 22 · see citing works
Cacciaglia, R., Salvadó, G., Molinuevo, J. L., Shekari, M., Falcón, C., Operto, G., Suárez‐Calvet, M., Milà‐Alomà, M., Sala, A., Rodriguez‐Vieitez, E., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01436-7 · Cited by 23 · see citing works
ABCA7 Genotypes Confer Alzheimer’s Disease Risk by Modulating Amyloid-β Pathology
Zhao, Q., Initiative, A. D. N., Wan, Y., Wang, H.-F., Sun, F.-R., Hao, X., Tan, M., Tan, C., Zhang, D., Tan, L., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151005 · Cited by 20 · see citing works
Weston, P. S. J., Paterson, R. W., Marc Modat, A., Burgos, N., Cardoso, M. J., Magdalinou, N. K., Lehmann, M., Dickson, J. C., Barnes, A., Bomanji, J. B., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.10.001 · Cited by 19 · see citing works
Key biomarkers in Alzheimer’s disease: Insights for diagnosis and treatment strategies
Jamal, R., Shaikh, M. A., Taleuzzaman, M., Haque, Z., Albratty, M., Alam, M. S., Makeen, H. A., Zoghebi, K. A., & Saleh, S. F. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251330500 · Cited by 19 · see citing works
Expanding the Repertoire of Biomarkers for Alzheimer’s Disease: Targeted and Non-targeted Approaches
Galasko, D. R. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00256 · Cited by 18 · see citing works
Gao, R., Zhang, G., Chen, X., Yang, A., Smith, G. S., Wong, D. F., & Zhou, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164762 · Cited by 17 · see citing works
Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity
Mastenbroek, S. E., Sala, A., García, D. V., Shekari, M., Salvadó, G., Lorenzini, L., Pieperhoff, L., Wink, A. M., Alves, I. L., Wolz, R., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209419 · Cited by 16 · see citing works
Reijntjes, R. H. A. M., Potters, W. V., Kerkhof, F. I., van Zwet, E. W., van Rossum, I. A., Verhamme, C., & Tannemaat, M. R. (2021) · Clinical Neurophysiology · doi:10.1016/j.clinph.2021.04.013 · Cited by 16 · see citing works
Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study
Guillén, N., Contador, J., Buongiorno, M., Álvarez, I., Cullell, N., Alcolea, D. A., Lleó, A., Fortea, J., Piñol‐Ripoll, G., Carnes, A., et al. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01701-y · Cited by 15 · see citing works
New PET markers for the diagnosis of dementia
Payoux, P., & Salabert, A. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000489 · Cited by 13 · see citing works
Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer’s Disease
Gomar, J. J., Conejero-Goldberg, C., Davies, P., Goldberg, T. E., & Initiative, F. T. A. D. N. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150937 · Cited by 13 · see citing works
Jiang, C., Wang, Q., Xie, S., Chen, Z., Fu, L., Peng, Q., Liang, Y., Guo, H., Guo, T., & Initiative, A. D. N. (2022) · Brain Communications · doi:10.1093/braincomms/fcac084 · Cited by 14 · see citing works
Correlation of florbetaben PET imaging and the amyloid peptide Aß42 in cerebrospinal fluid
Schipke, C. G., Koglin, N., Bullich, S., Joachim, L. K., Haas, B., Seibyl, J. P., Barthel, H., Sabri, O., & Peters, O. (2016) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2016.10.011 · Cited by 13 · see citing works
Avants, B., Hutchison, R. M., Mikulskis, A., Salinas-Valenzuela, C., Hargreaves, R., Beaver, J. D., & Chiao, P. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.10.002 · Cited by 10 · see citing works
Szalárdy, L., Zádori, D., Klivènyi, P., & Vécsei, L. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160037 · Cited by 9 · see citing works
Teipel, S. J., Dyrba, M., Vergallo, A., Lista, S., Habert, M. O., Potier, M., Lamari, F., Dubois, B., Hampel, H. J., & Grothe, M. J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.748198 · Cited by 7 · see citing works
Sacchi, L., Carandini, T., Fumagalli, G., Pietroboni, A. M., Contarino, V. E., Siggillino, S., Arcaro, M., Fenoglio, C., Zito, F., Marotta, G., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210593 · Cited by 6 · see citing works
Abe, Y., Kimura, N., Takahashi, R., Gotou, M., Mizukami, K., Uchida, H., & Matsubara, E. (2017) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.12991 · Cited by 5 · see citing works
Challenges in Alzheimer’s Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences
Lombardi, G., Pupi, A., Bessi, V., Polito, C., Padiglioni, S., Ferrari, C., Lucidi, G., Berti, V., Cristofaro, M. T. D., Piaceri, I., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200119 · Cited by 5 · see citing works
Aksnes, M., Müller, E. G., Tiiman, A., Edwin, T. H., Terenius, L. Y., Revheim, M.-E. R., Vukojević, V. B., Bogdanović, N., & Knapskog, A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200237 · Cited by 5 · see citing works
Aβ Imaging in Aging, Alzheimer’s Disease and Other Neurodegenerative Conditions
Villemagne, V. L., Fodero‐Tavoletti, M. T., Yates, P. A., Masters, C. L., & Rowe, C. C. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_10 · Cited by 4 · see citing works
Where Should I Draw the Line: PET-Driven, Data-Driven, or Manufacturer Cut-Off?
Sánchez‐Soblechero, A., López‐García, S., Lage, C., Fernández‐Matarrubia, M., Irure, J., López‐Hoyos, M., Jiménez-Bonilla, J. F., Quirce, R., de Arcocha-Torres, M., Cuenca-Vera, O., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230678 · Cited by 2 · see citing works
Chie, J. A. K. C., Persohn, S. A., Pandey, R. S., Simcox, O. R., Carter, G., Salama, P., Territo, P. R., & Initiative, A. D. N. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71218 · Cited by 2 · see citing works
Nordengen, K., Pålhaugen, L., Bettella, F., Bahrami, S., Selnes, P., Jarholm, J. A., Athanasiu, L., Shadrin, A. A., Andreassen, O. A., & Fladby, T. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12350 · Cited by 2 · see citing works
Sparse nonparametric regression with regularized tensor product kernel
Yu, H., Wang, Y., & Zeng, D. (2020) · Stat · doi:10.1002/sta4.300 · Cited by 1 · see citing works
Aβ Imaging in Aging, Alzheimer’s Disease, and Other Neurodegenerative Conditions
Villemagne, V. L., Doré, V., Burnham, S. C., & Rowe, C. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_10 · Cited by 1 · see citing works
Ong, K. T. (2018) · OBM Geriatrics · doi:10.21926/obm.geriatr.1803011
Nobili, F. M., Cagnin, A., Calcagni, M. L., Chincarini, A., Guerra, U. P., Morbelli, S. D., Padovani, A., Paghera, B., Pappatà, S., Parnetti, L., et al. (2019) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.18.03069-8
The Longitudinal Relationships between Biomarkers of Alzheimer’s Disease
Krance, S. H. (2019) · TSpace (University of Toronto)
Yang, X., Shang, J., Tong, Q., & Han, Q. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04693-z
Hosseini, S. F., Akbarabadi, P., Noorani, F., Kazemi, D., Sadeghsalehi, H., Fattahpour, M., Sheybani‐Arani, M., Noroozi, M., Kazemi, A., & Initiative, A. D. N. (2025) · Current Alzheimer Research · doi:10.2174/0115672050379856250529113023
- Authors
- Toledo, J. B., Bjerke, M., Da, X., Landau, S. M., Foster, N. L., Jagust, W., Jack, C., Weiner, M., Davatzikos, C., Shaw, L. M., & Trojanowski, J. Q.
- Affiliations
- University of Pennsylvania (US)
- University of California, Berkeley (US)
- University of Utah (US)
- Mayo Clinic (US)
- San Francisco VA Medical Center (US)
- Corresponding author
- Trojanowski, John Q.
- ORCID
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2015-05-01
- Volume
- 72
- Issue
- 5
- Pages
- 571
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC5642905
- OpenAlex
- W2042397283
- Cited by
- 88
- References
- 49
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 11 · 2019: 12 · 2018: 11 · 2017: 8 · 2016: 17 · 2015: 8 · 2014: 1
- FWCI
- 11.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904, R01 AG37551, R01AG043392, U01AG06786, U01AG006786, P30AG010124, P01AG017586, R01AG011378, P30AG013846, R01AG037551, R01AG041851, P01AG032953)
- National Heart, Lung, and Blood Institute (U01HL096917)
- National Institute of Neurological Disorders and Stroke (P50NS053488)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, florbetapir PET, APOE genotype, standardized uptake value ratio, cognitive decline, Alzheimer's Disease Neuroimaging Initiative, mixture models, unsupervised classification, biomarker validation
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Cross-Sectional Studies, Ethylene Glycols, Female, Humans, Longitudinal Studies, Male, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
